Table 1 Clinical characteristics of the patients

Age (years)

46.1 ± 11.4

45.9 ± 11.6

46.9 ± 10.9

0.605^a

Gender

0.223^b

Male

164 (75.2%)

127 (73.4%)

37 (82.2%)

Female

54 (24.8%)

46 (26.6%)

8 (17.8%)

Albumin (g/L)

43.6 ± 3.5

43.8 ± 3.5

43.1 ± 3.5

0.282^a

Hemoglobin (g/L)

135.3 ± 15.3

135.1 ± 15.2

136.2 ± 15.6

0.661^a

NLR

2.6 (1.9–3.4)

2.5 (1.9–3.4)

2.7 (2.0–3.5)

0.356^c

T category

0.575^d

T1

8 (3.7%)

5 (2.9%)

3 (6.7%)

T2

11 (5.0%)

10 (5.8%)

1 (2.2%)

T3

83 (38.1%)

66 (38.2%)

17 (37.8%)

T4

116 (53.2%)

92 (53.2%)

24 (53.3%)

N category

0.643^b

N0

17 (7.8%)

15 (8.7%)

2 (4.4%)

N1

91 (41.7%)

71 (41.0%)

20 (44.4%)

N2

84 (38.5%)

68 (39.3%)

16 (35.6%)

N3

26 (11.9%)

19 (11.0%)

7 (15.6%)

Stage

 > 0.999^d

I

1 (0.5%)

1 (0.6%)

0 (0%)

II

12 (5.5%)

10 (5.8%)

2 (4.4%)

III

78 (35.8%)

62 (35.8%)

16 (35.6%)

IV

127 (58.3%)

100 (57.8%)

27 (60.0%)

Induction chemotherapy

0.902^b

Yes

71 (32.6%)

56 (32.4%)

15 (33.3%)

No

147 (67.4%)

117 (67.6%)

30 (66.7%)

Concurrent chemotherapy

0.159^b

Yes

202 (92.7%)

163 (94.2%)

39 (86.7%)

No

16 (7.3%)

10 (5.8%)

6 (13.3%)

Adjuvant chemotherapy

0.751^b

Yes

116 (53.2%)

93 (53.8%)

23 (51.1%)

No

102 (46.8%)

80 (46.2%)

22 (48.9%)